Vagal Stimulation, Through its Nicotinic Action, Limits Infarct Size and the Inflammatory Response to Myocardial Ischemia and Reperfusion

被引:140
作者
Calvillo, Laura [2 ]
Vanoli, Emilio [3 ,4 ]
Andreoli, Elisa [4 ]
Besana, Alessandra [2 ]
Omodeo, Elisabetta [5 ]
Gnecchi, Massimiliano [1 ,3 ]
Zerbi, Pietro [5 ]
Vago, Gianluca [5 ]
Busca, Giuseppe [6 ]
Schwartz, Peter J. [1 ,3 ,7 ,8 ]
机构
[1] Fdn IRCCS Policlin S Matteo, Dept Cardiol, I-27100 Pavia, Italy
[2] IRCCS Ist Auxol Italiano, Lab Cardiovasc Genet, Milan, Italy
[3] Univ Pavia, Cardiol Sect, Dept Lung Blood & Heart, I-27100 Pavia, Italy
[4] Policlin Monza, Dept Cardiol, Monza, Italy
[5] Univ Milan, Pathol Unit, Inst Biomed Sci, L Sacco Hosp, Milan, Italy
[6] Univ Milan, Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Dept Cardiovasc Med, Milan, Italy
[7] Univ Cape Town, Dept Med, Cardiovasc Genet Lab, Hatter Inst Cardiovasc Res Africa, ZA-7700 Rondebosch, South Africa
[8] King Saud Univ, Coll Med, Dept Family & Community Med, Riyadh 11461, Saudi Arabia
关键词
vagal activity; ischemia/reperfusion; myocardial infarction; autonomic nervous system; infarct size; inflammatory markers; CHOLINERGIC ANTIINFLAMMATORY PATHWAY; ACUTE CORONARY SYNDROMES; CHRONIC HEART-FAILURE; NERVE-STIMULATION; CONSCIOUS DOGS; SUDDEN-DEATH; INJURY; ACETYLCHOLINE; ASSOCIATION; MECHANISMS;
D O I
10.1097/FJC.0b013e31822b7204
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Vagal activity has protective effects in ischemic heart disease. We tested whether vagal stimulation (VS) could modulate the inflammatory reaction, a major determinant of cardiac injury after ischemia/reperfusion. Four groups of male rats underwent myocardial ischemia (30 minutes) and reperfusion (24 hours). One group underwent VS (40 minutes), 1 VS plus atrial pacing (VS + Pacing), and 1 VS plus nicotinic inhibition by mecamylamine (VS + MEC). After 24 hours, the area at risk, infarct size, inflammation parameters, and apoptosis were quantified. Infarct size was reduced in all VS-treated rats (controls, 53 +/- 18%; VS, 6.5 +/- 3%; VS + Pacing, 23 +/- 6%; VS + MEC, 33 +/- 9%; P < 0.005 vs. controls). The infarct size in the VS + MEC group was larger than that in VS-treated animals, despite similar heart rate, suggesting partial loss of protection. The number of macrophages, neutrophils, and apoptotic cells in the area at risk and the plasma cytokines levels were significantly reduced in all VS-treated animals. In conclusion, VS decreases infarct size and inflammatory markers during ischemia/reperfusion independent of the heart rate. The anti-inflammatory and antiapoptotic properties of the nicotinic pathway are the primary underlying mechanism. The vagally mediated modulation of inflammatory responses may prove valuable in the clinical management of acute coronary syndromes and of heart failure.
引用
收藏
页码:500 / 507
页数:8
相关论文
共 33 条
[1]   Elevated circulating levels of C-C chemokines in patients with congestive heart failure [J].
Aukrust, P ;
Ueland, T ;
Müller, F ;
Andreassen, AK ;
Nordoy, I ;
Aas, H ;
Kjekshus, J ;
Simonsen, S ;
Froland, SS ;
Gullestad, L .
CIRCULATION, 1998, 97 (12) :1136-1143
[2]   Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes [J].
Baldus, S ;
Heeschen, C ;
Meinertz, T ;
Zeiher, AM ;
Eiserich, JP ;
Münzel, T ;
Simoons, ML ;
Hamm, CW .
CIRCULATION, 2003, 108 (12) :1440-1445
[3]  
Chandrasekar B, 2001, CIRCULATION, V103, P2296
[4]   Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure [J].
De Ferrari, Gaetano M. ;
Crijns, Harry J. G. M. ;
Borggrefe, Martin ;
Milasinovic, Goran ;
Smid, Jan ;
Zabel, Markus ;
Gavazzi, Antonello ;
Sanzo, Antonio ;
Dennert, Robert ;
Kuschyk, Juergen ;
Raspopovic, Srdjan ;
Klein, Helmut ;
Swedberg, Karl ;
Schwartz, Peter J. .
EUROPEAN HEART JOURNAL, 2011, 32 (07) :847-855
[5]   Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions [J].
De Ferrari, Gaetano M. ;
Schwartz, Peter J. .
HEART FAILURE REVIEWS, 2011, 16 (02) :195-203
[6]   Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes [J].
de Lemos, JA ;
Morrow, DA ;
Sabatine, MS ;
Murphy, SA ;
Gibson, CM ;
Antman, EM ;
McCabe, CH ;
Cannon, CP ;
Braunwald, E .
CIRCULATION, 2003, 107 (05) :690-695
[7]   POSTREPERFUSION INFLAMMATION - A MODEL FOR REACTION TO INJURY IN CARDIOVASCULAR-DISEASE [J].
ENTMAN, ML ;
SMITH, CW .
CARDIOVASCULAR RESEARCH, 1994, 28 (09) :1301-1311
[8]   Chemokines in the ischemic myocardium: from inflammation to fibrosis [J].
Frangogiannis, NG .
INFLAMMATION RESEARCH, 2004, 53 (11) :585-595
[9]   Cytokines and the microcirculation in ischemia and reperfusion [J].
Frangogiannis, NG ;
Youker, KA ;
Rossen, RD ;
Gwechenberger, M ;
Lindsey, MH ;
Mendoza, LH ;
Michael, LH ;
Ballantyne, CM ;
Smith, CW ;
Entman, ML .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1998, 30 (12) :2567-2576
[10]   Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy [J].
Frangogiannis, Nikolaos G. ;
Dewald, Oliver ;
Xia, Ying ;
Ren, Guofeng ;
Haudek, Sandra ;
Leucker, Thorsten ;
Kraemer, Daniela ;
Taffet, George ;
Rollins, Barrett J. ;
Entman, Mark L. .
CIRCULATION, 2007, 115 (05) :584-592